When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool

European Urology

Volumn 57, Issue 4, 2010, Pages 551-558

  Briganti, Alberto ^a   Passoni, Niccolò ^a   Ferrari, Matteo ^a   Capitanio, Umberto ^a   Suardi, Nazareno ^a   Gallina, Andrea ^a   Pozzo, Luigi Filippo Da ^b   Picchio, Maria ^c   Di Girolamo, Valerio ^a   Salonia, Andrea ^a   Gianolli, Liugi ^c   Messa, Cristina ^d   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Bone metastases; Bone scan; Guidelines; Prostate cancer; Staging

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EXTERNAL VALIDITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AREA UNDER CURVE; BIOPSY; BONE NEOPLASMS; DECISION SUPPORT TECHNIQUES; HUMANS; ITALY; LEAST-SQUARES ANALYSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TECHNETIUM TC 99M MEDRONATE; TIME FACTORS;

EID: 77249168161     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.12.023     Document Type: Article

References (34)

1. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Bray F., Sankila R., Ferlay J., and Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 (2002) 99-166
3. Black R.J., Bray F., Ferlay J., and Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33 (1997) 1075-1107
4. Carlin B.I., and Andriole G.L. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 88 Suppl 12 (2000) 2989-2994
5. Rigaud J., Tiguert R., Le Normand L., et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168 (2002) 1423-1426
6. Groot M.T., Boeken Kruger C.G.G., Pelger R.C.M., and Uyl-de Groot C.A. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 43 (2003) 226-232
7. Gallina A., Chun F.K., Suardi N., et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 101 (2008) 1513-1518
8. Ryan C.J., Elkin E.P., Small E.J., Duchane J., and Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 24 (2006) 396-402
9. National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in urological cancers. The manual. National Institute for Health and Clinical Excellence Web site. http://www.nice.org.uk/nicemedia/pdf/Urological_Manual.pdf. Updated September 2002.
10. Halabi S., Vogelzang N.J., Kornblith A.B., et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26 (2008) 2544-2549
11. Schaffer D.L., and Pendergrass H.P. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121 (1976) 431-434
12. Thurairaja R., McFarlane J., Traill Z., and Persad R. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 94 (2004) 268-271
13. Chybowski F.M., Keller J.J., Bergstralh E.J., and Oesterling J.E. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145 (1991) 313-318
14. Lee N., Fawaaz R., Olsson C.A., et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 48 (2000) 1443-1446
15. Ataus S., Citçi A., Alici B., et al. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int Urol Nephrol 31 (1999) 481-489
16. Oesterling J.E., Martin S.K., Bergstralh E.J., and Lowe F.C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 (1993) 57-60
17. Gleave M.E., Coupland D., Drachenberg D., et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 47 (1996) 708-712
18. Lin K., Szabo Z., Chin B.B., and Civelek A.C. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 24 (1999) 579-582
19. Haukaas S., Roervik J., Halvorsen O.J., and Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?. Br J Urol 79 (1997) 770-776
20. Lorente J.A., Valenzuela H., Morote J., and Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26 (1999) 625-632
21. Kemp P.M., Maguire G.A., and Bird N.J. Which patients with prostatic carcinoma require a staging bone scan?. Br J Urol 79 (1997) 611-614
22. Bruwer G., Heyns C.F., and Allen F.J. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 35 (1999) 223-227
23. Salonia A., Gallina A., Camerota T.C., et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology 68 (2006) 362-366
24. Kosuda S., Yoshimura I., Aizawa T., et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 94 (2002) 964-972
25. Rudoni M., Antonini G., Favro M., et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 22 (1995) 207-211
26. Wolff J.M., Zimny M., Borchers H., Wildberger J., Buell U., and Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?. Eur Urol 33 (1998) 376-381
27. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
28. Clinical recommendations. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
29. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). American Joint Committee on Cancer staging manual. 6th ed. (2002), Springer, Philadelphia, PA
30. Hricak H., Choyke P.L., Eberhardt S.C., Leibel S.A., and Scardino P.T. Imaging prostate cancer: a multidisciplinary perspective. Radiology 243 (2007) 28-53
31. Gemmel F.F., and De Geeter F.W. Magnetic resonance imaging versus bone scan in high-risk prostatic carcinoma: some methodological considerations. J Clin Oncol 26 (2008) 1189-1190
32. Venkitaraman R., Sohaib A., and Cook G. MRI or bone scan or both for staging of prostate cancer?. J Clin Oncol 25 (2007) 5837-5838
33. Laussen B., Sauerbrei W., and Schumacher M. Classification and regression trees used for the exploration of prognostic factors measured in different scales. In: Dirschedl P., and Ostermann R. (Eds). Computational statistics (1994), Heidelberg, Physica-Verlag, Germany
34. Lecouvet F.E., Geukens D., Stainier A., et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25 (2007) 3281-3287